Biopharma Dealmaking Quarterly Statistics, Q2 2013

A look at the financing, M&A, and alliance activity April-June 2013

Q2 2013 biopharma financing increased 139% to $11 billion over Q1’s $4.6 billion, thanks mostly to two huge transactions by Valeant to fund its $8.7 billion takeover of ophthalmics player Bausch & Lomb, the company’s largest acquisition to date. Options and antibody-drug conjugates featured prominently in the alliances.

From April through June 2013, 134 financings brought in over $11 billion, a steep increase over the previous three-months’ $4.6 billion. Similar to the preceding quarter, follow-on public offerings yielded the most capital by comparison with other financing vehicles ( $3.8 billion in aggregate, or 35% of the total biopharma dollars raised. (See Exhibit 1.) Valeant Pharmaceuticals International Inc.’s $2.3 billion June FOPO, in which it sold 27 million shares at $85 apiece, [See Deal] made up 60% of the FOPO category. The quarter’s largest transaction was also done by Valeant, in June: a $3.2 billion debt offering. [See Deal] The company sold notes to VPII Escrow Corp., issuing $1.6 billion of its 6.75% senior unsecured notes due 2018 and $1.625 billion of its 7.5% senior unsecured notes due 2021. Valeant will use the proceeds to help finance its $8.7 billion acquisition of eye care specialist Bausch & Lomb Inc., [See Deal] which had planned an IPO in March, but then withdrew the offering in May. [See Deal]

Interested in getting an alert each time we publish a quarterly review of biopharma dealmaking? Click here

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.